Tender detail
Amiwantamab for the treatment of lung cancer and pleural mesothelioma (B.6)
Summary
The procurement concerns the 12-month supply of Amiwantamab for the treatment of lung cancer and pleural mesothelioma, in a subcutaneous dosage form. No variants, options or lots are provided for. Price is the only award criterion, weighted at 100%. Bids must be submitted electronically through the e-proPublico platform by 17 September 2026 at 11:00. The required declarations, product documentation and evidence of the necessary pharmaceutical trading authorisations must be submitted with the bid.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.